Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
Adolescent
Adult
Aged
Aged, 80 and over
Community Health Planning
Female
Hematologic Neoplasms
/ epidemiology
Hematopoietic Stem Cell Transplantation
/ statistics & numerical data
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Public Health
/ statistics & numerical data
Risk Factors
Transplantation, Homologous
/ statistics & numerical data
Treatment Outcome
United States
/ epidemiology
Young Adult
allogeneic transplant
community health
hematopoietic cell transplantation
survival
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
30
01
2020
revised:
01
07
2020
accepted:
27
07
2020
pubmed:
22
10
2020
medline:
23
9
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes. This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied. The median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM. Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
Sections du résumé
BACKGROUND
The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.
METHODS
This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.
RESULTS
The median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.
CONCLUSIONS
Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
Identifiants
pubmed: 33085090
doi: 10.1002/cncr.33232
pmc: PMC7855526
mid: NIHMS1642562
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
609-618Subventions
Organisme : Sanofi Genzyme
Organisme : Office of Naval Research
ID : N00014-18-1-2850
Organisme : NHLBI NIH HHS
ID : U01 HL128568
Pays : United States
Organisme : Adaptive Biotechnologies
Organisme : Sobi, Inc
Organisme : NCI NIH HHS
ID : R01 CA152108
Pays : United States
Organisme : Novartis Oncology
Organisme : Kyowa Kirin
Organisme : Genzyme
Organisme : OncoImmune, Inc
Organisme : NIAID NIH HHS
ID : U01 AI126612
Pays : United States
Organisme : Orca Biosystems, Inc
Organisme : Mesoblast
Organisme : Regeneron Pharmaceuticals
Organisme : Health Resources and Services Administration (HRSA)
ID : HHSH250201700006C
Organisme : Kite Pharma
Organisme : HistoGenetics
Organisme : Daiichi Sankyo Co
Organisme : Bluebird Bio
Organisme : NHLBI NIH HHS
ID : R21 HL140314
Pays : United States
Organisme : Health Resources and Services Administration (HRSA)
ID : HHSH250201700007C
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : Actinium Pharmaceuticals
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : Millennium (the Takeda Oncology Co)
Organisme : Janssen/Johnson & Johnson
Organisme : AlloVir
Organisme : Jazz Pharmaceuticals
Organisme : NIAID NIH HHS
ID : U01 AI069197
Pays : United States
Organisme : AstraZeneca
Organisme : NCI NIH HHS
ID : R01 CA231141
Pays : United States
Organisme : Adienne SA
Organisme : Kiadis Pharma
Organisme : Amgen
Organisme : Medical College of Wisconsin
Organisme : Novartis Pharmaceuticals Corporation
Organisme : Gamida-Cell
Organisme : Incyte Corporation
Organisme : Pharmacyclics, LLC
Organisme : The National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID)
ID : U24CA076518
Organisme : Janssen Biotech
Organisme : NHLBI NIH HHS
ID : R01 HL129472
Pays : United States
Organisme : CytoSen Therapeutics
Organisme : Viracor Eurofins
Organisme : REGiMMUNE Corp
Organisme : Astellas Pharma US
Organisme : Takeda Oncology
Organisme : AbbVie
Organisme : Seattle Genetics
Organisme : Celgene
Organisme : Merck & Company, Inc
Organisme : Terumo BCT
Organisme : Bristol-Myers Squibb
Organisme : Miltenyi Biotec
Organisme : Anthem
Organisme : Chimerix
Organisme : Atara Biotherapeutics
Organisme : Pfizer
Organisme : Health Resources and Services Administration (HRSA)
ID : SC1MC31881-01-00
Organisme : CSL Behring
Organisme : Medac GmbH
Organisme : GlaxoSmithKline
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218285
Pays : United States
Organisme : Janssen Pharmaceuticals
Organisme : Legend Biotech
Organisme : Merck Sharp & Dohme Corp
Organisme : NHLBI NIH HHS
ID : R01 HL130388
Pays : United States
Organisme : NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215134
Pays : United States
Organisme : Xenikos BV
Organisme : Takeda Pharma
Organisme : Office of Naval Research
ID : N00014-18-1-2888
Organisme : NHLBI NIH HHS
ID : R01 HL131731
Pays : United States
Organisme : Omeros Corporation
Organisme : NHLBI NIH HHS
ID : R01 HL126589
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL150232
Pays : United States
Organisme : Mallinckrodt LLC
Organisme : NIAID NIH HHS
ID : R01 AI128775
Pays : United States
Organisme : Office of Naval Research
ID : N00014-20-1-2705
Organisme : Magenta Therapeutics
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2020 American Cancer Society.
Références
Bone Marrow Transplant. 2016 Sep;51(9):1233-40
pubmed: 27088381
Biol Blood Marrow Transplant. 2015 Apr;21(4):701-6
pubmed: 25555447
Cancer. 2010 Jul 15;116(14):3469-76
pubmed: 20564154
Blood. 2010 Jan 14;115(2):206-14
pubmed: 19897583
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Popul Health Metr. 2015 Apr 17;13:11
pubmed: 25931988
Biol Blood Marrow Transplant. 2018 Apr;24(4):877-879
pubmed: 29292058
Blood Adv. 2017 Aug 22;1(19):1617-1627
pubmed: 29296802
Health Serv Res. 2015 Feb;50(1):197-216
pubmed: 25047947
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Am J Transplant. 2013 Sep;13(9):2374-83
pubmed: 24034708
Biol Blood Marrow Transplant. 2019 Oct;25(10):2086-2090
pubmed: 31228584
Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399
pubmed: 29032275
J Clin Oncol. 1997 Jul;15(7):2644-51
pubmed: 9215836
Biol Blood Marrow Transplant. 2010 Aug;16(8):1070-5
pubmed: 20036337
Am J Transplant. 2017 Mar;17(3):617-621
pubmed: 27696682
Laryngoscope. 2016 Mar;126(3):775-81
pubmed: 26372521
Bone Marrow Transplant. 2019 Sep;54(9):1443-1452
pubmed: 30696998
Biol Blood Marrow Transplant. 2015 Oct;21(10):1830-8
pubmed: 26116089
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Lifetime Data Anal. 2008 Dec;14(4):389-404
pubmed: 18836830
Cancer. 2017 Aug 15;123(16):3141-3149
pubmed: 28472539
Arch Surg. 2012 Jun;147(6):520-6
pubmed: 22351876
Bone Marrow Transplant. 2012 Nov;47(11):1385-90
pubmed: 22056642
Bone Marrow Transplant. 2015 Oct;50(10):1326-30
pubmed: 26191953
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224